Redsense Medical 株価情報 (OTC: RDSNF)

最新ニュース Redsense Medical (OTC:RDSNF) 株価情報

Redsense Medical AB manufactures and sells blood loss detection devices in Sweden. The company has developed a monitoring system that can detect the first sign of a blood leak using patented fiber optic technology. The products of the company include Alarm Unit, Venous Needle Patch, Sensor Patch, and others.

Redsense Medical AB

Truist Securities analyst Joel Fishbein maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Hold and lowers the price target from $38 to $35.

News

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Rapid7, Lowers Price Target to $35

<ul>
<li>RDDT</li>
<li>TSLA</li>
<li>BABA</li>
<li>HOOD</li>
<li>NVDA</li>
<li>INTC</li>
<li>GOOGL</li>
<li>PLTR</li>
<li>BBAI</li>
<li>SMCI</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

BABA

BBAI

GOOGL

HOOD

INTC

NVDA

PLTR

RDDT

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of February 13, 2025 (Via Swaggy Stocks)

OneConnect Financial Technology Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) shares are trading higher premarket on Thursday after the company launched its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43687266/oneconnect-integrates-deepseek-into-ai-agent-platform" rel="noreferrer noopener">proprietary AI Agent Platform</a>.
The platform integrates advanced open-source large language models, including DeepSeek and Qwen, to deliver an AI-driven solution tailored for the banking industry.
OneConnect has adopted a dual-engine approach, combining an &#8220;Open-Source Large Language Model + AI Agent Platform&#8221; to harness the versatility of open-source models while refining them for the specific needs of the banking sector.
This strategy enhances the platform's adaptability, enabling sophisticated semantic understanding, logical reasoning, and multi-turn interactions in real-world banking applications.
The company also utilizes model compression and knowledge distillation techniques to lower computational costs, delivering more efficient and cost-effective AI solutions for banks.
This initiative aims to accelerate digital transformation, enhancing operational efficiency and customer experience through advanced AI capabilities.
Price Action: OCFT shares are up 14.6% at $3.76 premarket at the last check
Read Next:
<ul>
<li><a href="https://www.benzinga.com/startups/25/02/43599833/data-on-deepseek-may-be-somehow-weaponized-against-the-united-states-suze-orman-says-the-ai-app-faces-similar-fate-as-tiktok" target="_blank" rel="noreferrer noopener">Data On DeepSeek May &#8216;Be Somehow Weaponized Against The United States&#8217; &#8211; Suze Orman Says The AI App Faces Similar Fate As TikTok</a></li>
</ul>
Image: Shutterstock

Equities

Small Cap

Movers

OCFT

OneConnect Unveils AI Agent Platform, Boosting Banking Efficiency and Innovation

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for&nbsp;APRETUDE (cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-1 negative.1
ViiV Healthcare is committed to ensuring timely public access for APRETUDE to help reduce the risk of sexually acquired HIV-1 infection and make progress towards global targets of ending HIV by 2030, which Canada endorsed.2,3&nbsp;ViiV Healthcare recognizes the pCPA's efforts and shared commitment to achieving this goal. This milestone underscores the need to expedite public reimbursement and as such, ViiV Healthcare looks forward to working with provincial and territorial governments and other stakeholders to make APRETUDE available through public drug plans.
APRETUDE is the first and only long-acting injectable approved in Canada and is indicated for at-risk adults and adolescents aged 12 years and older and weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1 infection. APRETUDE for PrEP has demonstrated superior efficacy to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF tablets) in reducing the risk of HIV acquisition in two clinical trials, giving Canadians more options for PrEP.1&nbsp;

Biotech

General

ViiV Healthcare And The Pan-Canadian Pharmaceutical Alliance Finalize Negotiations For APRETUDE For HIV-1 Pre-Exposure Prophylaxis

Tech

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

MicroCloud Hologram Highlights Use Of DeepSeek Model Related To Digital Simulated Quantum Computing

Truist Securities analyst Terry Tillman reiterates Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) with a Buy and raises the price target from $100 to $110.

Reiteration

QTWO

Truist Securities Reiterates Buy on Q2 Holdings, Raises Price Target to $110

Truist Securities analyst Keith Hughes maintains Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) with a Buy and lowers the price target from $670 to $610.

Truist Securities Maintains Buy on Martin Marietta Materials, Lowers Price Target to $610

WIIM

DGLY

Digital Ally shares are trading lower after the company priced a $15 million underwritten public offering.

HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) reported stronger-than-expected results for its fourth <a href="https://www.benzinga.com/quote/HUBS/earnings">quarter on Wednesday</a>.
HubSpot reported quarterly earnings of $2.32 per share, beating the $2.19 analysts consensus estimate. Quarterly revenue came in at $703.17 million, beating the $673.32 million consensus estimate.
"We had a solid finish to 2024, highlighting our leadership as a platform company", said Yamini Rangan, CEO of HubSpot. "2024 was a transformative year for HubSpot as we reimagined our product, our platform, and company with AI. I'm excited by the progress we've made in embedding AI across our hubs and the value it's driving for customers."
The company said it sees first-quarter revenue of between $697 million and $699 million, versus the $705.71 million estimate, and EPS of between $1.74 and $1.76, versus the $2.00 estimate
HubSpot shares gained 0.1% to close at $785.50 on Wednesday.
These analysts made changes to their price targets on HubSpot following earnings announcement.
<ul>
<li>Oppenheimer analyst Ken Wong maintained HubSpot with an Outperform and raised the price target from $850 to $900.</li>
<li>Piper Sandler analyst Brent Bracelin maintained HubSpot with a Neutral and raised the price target from $640 to $808.</li>
<li>Canaccord Genuity analyst David Hynes maintained the stock with a Buy and raised the price target from $710 to $900.</li>
<li>Morgan Stanley analyst Keith Weiss maintained HubSpot with an Overweight and boosted the price target from $835 to $898.</li>
<li>Barclays analyst Ryan Macwilliams maintained the stock with an Equal-Weight and raised the price target from $725 to $815.</li>
<li>Needham analyst Joshua Reilly maintained HubSpot with a Buy and raised the price target from $730 to $900.</li>
<li>Truist Securities analyst Terry Tillman reiterated the stock with a Buy and raised the price target from $750 to $900.</li>
</ul>
Considering buying HUBS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090907/image-122-1024x576.png" alt="" class="wp-image-781145" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090907/image-122-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090907/image-122-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090907/image-122-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090907/image-122.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Markets

HUBS

These Analysts Increase Their Forecasts On HubSpot Following Better-Than-Expected Earnings

Following Governor Youngkin's November announcement, Early Adopter Program Launches in Virginia, Highly Anticipated Defense Tech Drones, Body Cameras, AI Integration and International Expansion to Follow
This news follows: Wrap Technologies Launches Go-Forward Strategy, Advancing End-to-End Public Safety and Defense Solutions with New Virginia Facility
NORTON, Va., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) ("Wrap" or, the "Company") today announced the launch of its highly anticipated Managed Safety and Response (MSR) Connected Ecosystem in Virginia, with the aim of delivering a modern approach for law enforcement training, defensive tactics and real-time safety solutions. With past vocal support of Governor Glenn Youngkin and Virginia's public safety institutions, Wrap hopes to establish the Commonwealth as a leader in next-generation policing solutions.
As early adopters, Virginia agencies will be the first to benefit from Wrap's integrated approach, which combines enhanced training, automated support systems and a scalable ecosystem designed to seamlessly integrate follow-on technologies.
The Company is evolving to meet agency demand for integrated service delivery of disparate support technologies and embedded recurring training. This approach will see Wrap invest in a core group of world-class professional services leaders and then digitize value delivery through AI-powered workflows, ensuring exemplary customer satisfaction in its MSR service.

WRAP

Wrap Technologies Announces Launch Of Early Adopter Program In Virginia For Managed Safety Ecosystem; Focus On Drones, AI, Body Cameras; Plans International Expansion

<ul>
<li>Partnership Will Pave the Way for a Cost-Effective Path to Decarbonization Using Natural Gas and Sequestration</li>
<li>Offers Scalable, Near-Zero Approach That Uses Existing Fuel Infrastructure to Meet Today's Urgent Energy Needs</li>
</ul>
Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>), a global leader in fuel cell electricity generation, and Chart Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) ("Chart"), a global leader in energy and industrial gas solutions, announced today a carbon capture partnership that will use natural gas and fuel cells to generate near zero-carbon, always-on power. In announcing this partnership, the companies aim to offer a solution to customers, like data centers and manufacturers, who are seeking power solutions that can be deployed rapidly without compromising reliability or emission goals.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20250213775837/en/">https://www.businesswire.com/news/home/20250213775837/en/</a>
As part of the partnership, Chart will use its carbon capture know how to process Bloom's high-purity carbon dioxide (CO2) exhaust stream into outputs that are ready for utilization or sequestration. The CO2 utilization market serves as an important near-term term bridge to carbon sequestration in locations, where sequestration infrastructure is not available or permitted. According to Morgan Stanley, more than 500 million tonnes per annum (MTPA) of carbon storage capacity is expected to come online within the next five years. As sequestration capabilities grow in the U.S. and globally, CO2 utilization provides an immediate pathway to repurpose captured carbon while supporting long-term decarbonization efforts.
Efficient carbon capture depends on the purity of CO₂ in the exhaust stream, which varies widely across power generation technologies. Conventional technologies that generate electricity from natural gas through combustion—such as gas turbines and reciprocating engines—produce exhaust streams with approximately 5% CO₂. Capturing such low-concentration emissions remains technically complex and costly. In contrast, Bloom's proprietary high-temperature fuel cell technology converts natural gas without combustion, yielding a CO₂-rich stream that has 15 times lower mass flow and ten times the CO2 concentration, making the capture process more efficient and less costly.

GTLS

Bloom Energy And Chart Industries Announce Carbon Capture Partnership; Partnership Will Pave The Way For A Cost-Effective Path To Decarbonization Using Natural Gas And Sequestration

Buybacks

TSCO

Tractor Supply Increases Buyback By $1B

<a href="https://www.theinformation.com/briefings/apple-continues-to-work-with-baidu-on-ai-features-for-iphone-in-china" title="https://www.theinformation.com/briefings/apple-continues-to-work-with-baidu-on-ai-features-for-iphone-in-china">https://www.theinformation.com/briefings/apple-continues-to-work-with-baidu-on-ai-features-for-iphone-in-china</a>

AAPL

BIDU

The Information, Earlier: 'Apple Continues to Work with Baidu on AI Features for iPhone in China'

Dividends

Tractor Supply Increases Annual Dividend From $0.88 To $0.92

Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) (the "Company" or "Codere Online"), a leading online gaming operator in Spain and Latin America, today announced that, by letter received on February 12, 2025, the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") has determined to grant the Company's request to continue its listing on Nasdaq, subject to the Company filing its annual report on Form 20-F for the year ended December 31, 2023 (the "2023 Annual Report") on or before May 12, 2025.
The Panel's determination follows a hearing on January 16, 2025, at which the Panel considered the Company's plan to regain compliance with Listing Rule 5250(c)(1) (the "Rule"). The Company has and continues to work diligently with its new auditor to complete and file with the Securities and Exchange Commission ("SEC") its 2023 Annual Report and expects to do so within the extension period granted by the Panel, thereby regaining compliance with the Rule.
Following this positive development, the Company will release its fourth quarter 2024 results prior to 8:30AM US Eastern Time on Thursday, February 20, 2025. At 8:30AM US Eastern Time on the same day, Codere Online's management will host a conference call to discuss the results and provide a business update.

CDRO

Codere Online Granted Nasdaq Extension To File 2023 Annual Report By May 12, 2025; Q4 2024 Results To Be Released February 20, 2025

Management

LMAT

LeMaitre Vascular Appointed As CFO, Effective March 10, 2025

Contracts

PPSI

Pioneer Power Renews And Extends Service Agreement; Says It Is Expected To Generate ~$6M In Total Revenue Over The Course Of The Three-Year Agreement

Sprout Social Launches Rebranded Influencer Marketing Platform

INGR

Oobli Partners With Ingredion Announce Partnership To Accelerate Access To Sweetener Systems

Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported better-than-expected earnings for its fourth <a href="https://www.benzinga.com/quote/biib/earnings">quarter on Wednesday</a>.
The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.
Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million.
Biogen said it expects a full year 2025 adjusted EPS of $15.25-$16.25 versus a consensus of $16.34.
Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.
Biogen shares fell 4.3% to close at $133.43 on Wednesday.
These analysts made changes to their price targets on Biogen following earnings announcement.
<ul>
<li>Canaccord Genuity analyst Sumant Kulkarni maintained Biogen with a Buy and lowered the price target from $298 to $265.</li>
<li>Truist Securities analyst Srikripa Devarakonda maintained the stock with a Buy and slashed the price target from $220 to $210.</li>
<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained Biogen with a Buy and lowered the price target from $300 to $241.</li>
</ul>
Considering buying BIIB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="569" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png" alt="" class="wp-image-781120" style="width:574px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13090221/image-121.png 1135w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Earnings

BIIB

Biogen Analysts Lower Their Forecasts After Q4 Results

Redsense Medical

Comments

Redsense Medical

ニュース

最新ニュース Redsense Medical (OTC:RDSNF) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル